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ABSTRACT
An increasing number of bioinformatic tools designed to detect CNVs (copy number variants) in tumor
samples based on paired exome data where a matched healthy tissue constitutes the reference have been
published in the recent years. The idea of using a pool of unrelated healthy DNA as reference has previ-
ously been formulated but not thoroughly validated. As of today, the gold standard for CNV calling is still
aCGH but there is an increasing interest in detecting CNVs by exome sequencing. We propose to design
a metric allowing the comparison of two CNV proﬁles, independently of the technique used and assessed
the validity of using a pool of unrelated healthy DNA instead of a matched healthy tissue as reference
in exome-based CNV detection. We compared the CNV proﬁles obtained with three diﬀerent approaches
(aCGH, exome sequencing with a matched healthy tissue as reference, exome sequencing with a pool of
eight unrelated healthy tissue as reference) on three multiple myeloma samples. We show that the usual
analyses performed to compare CNV proﬁles (deletion/ampliﬁcation ratios and CNV size distribution)
lack in precision when confronted with low LRR values, as they only consider the binary status of each
CNV. We show that the metric-based distance constitutes a more accurate comparison of two CNV pro-
ﬁles. Based on these analyses, we conclude that a reliable picture of CNV alterations in multiple myeloma
samples can be obtained from whole-exome sequencing in the absence of a matched healthy sample.
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1 INTRODUCTION
Copy number variations (CNVs) are genomic modiﬁcations
responsible of phenotypic diversity but are also involved
in many pathologies like cardiovascular diseases, autoim-
mune diseases, neurodegenerative diseases, and cancers
(Beroukhim et al., 2010; Kim et al., 2013). In cancers chro-
mosomal alterations might lead to several speciﬁc genomic
proﬁles which can be linked to prognosis or response to treat-
ment, for example the ampliﬁcation of the ERBB2 gene in
breast cancer leads to its overexpression, and to sensitivity to
treatment by trastuzumab (Robert et al., 2006).
Multiple myeloma is a hematological cancer characterized
by a high level of CNV, implicating plasma cells. Some of
them are linked to an adverse prognosis: del(17)(p), del(1)(p),
dup(1)(q), and del(13) (Fonseca et al., 2004; Walker et al.,
2010). On the other hand, hyper-diploidies involving odd
chromosomes are rather associated with a favorable outcome
(Smadja et al., 2001). CNV assessment during treatment
course of these malignancies is also essential to evaluate dis-
ease progression (Avet-Loiseau et al., 2009; Chung,Mulligan,
Fonseca, & Chng, 2013).
Traditionally, CNV detection has been performed with
cytogenetic techniques such as ﬂuorescent in situ hybridiza-
tion (FISH). Comparative genomic hybridization arrays
(aCGH) are currently considered as the reference technology
to measure genomic alterations. However, next-generation
sequencing (NGS) could soon become an essential tool for
cancer study as it allows the detection of punctual mutations
and insertions/deletions. Moreover, whole genome sequenc-
ing (WGS) can also be used for the detection of CNVs and
displays a higher resolution than aCGH, down to 40 bp (Xi
et al., 2011). However in the clinical ﬁeld, WGS is too expen-
sive and WES or targeted sequencing is more commonly con-
sidered. CNV are more easily computed from WGS data,
as the entire genome is theoretically sequenced at constant
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coverage and one does not have to take into account the inter-
probe coverage variability that arises in WES (Hwang et al.,
2015; Liu et al., 2013). That being said, WES focuses on a
highly function-enriched subset of the genome and it requires
smaller computational resources for processing and storage of
the data than WGS. For these reasons, a number of dedicated
computational algorithms have been developed to accurately
retrieve segmental CNV from WES data (Guo et al., 2013;
Tan et al., 2014).
Several factors are responsible for biases in CNV detection:
GC rich fragments, variability of the fragmentation process
during library preparation, or copy number polymorphisms.
Most of the bioinformatic tools set-up for CNV detection in
tumor by WES consider these potential biases and try to min-
imize them (Xi et al., 2011). Some of the algorithms designed
to detect CNVon tumor samples also require amatched paired
healthy tissue sampled from the same patient, as they use the
read depth ratio between tumor and healthy sample to infer
the copy number at each locus. This control sample needs to
be compiled from the same technological platform. However,
such paired reference tissue is very seldom available, espe-
cially in large epidemiology studies, and could theoretically
be replaced by the use of a pool of unrelated healthy tissues
from patients of the same ethnicity (Sathirapongsasuti et al.,
2011). However, no data are currently available in the liter-
ature to state if this solution would allow the acquisition of
comparable CNV results.
To evaluate if the replacement of the matched paired
healthy tissue with a pool of unrelated healthy tissue confers
the same results, we have compared the performances of these
two reference types against results obtained by aCGH, consid-
ered as the gold standard.
The whole study was conducted on a multiple myeloma
(MM) cohort. Malignant cells population was enriched by
positive selection, and analyzed by WES (Nextera, Illumina)
and aCGH (SureSelect, Agilent).
2 MATERIALS
2.1 Ethical concerns
Ethics approval was obtained from the Institutional Review
Board (Ethical Committee of the Faculty of Medicine of the
University of Liège) in compliance with the Declaration of
Helsinki. All patients signed a written informed consent form.
This work consisted of a prospective study and did not lead to
any change in the treatment of enrolled patients.
2.2 Patients and sample preparation
Bone marrow samples of 10 MM patients were obtained
from CHU of Liège. CD138 human MicroBeads (Miltenyi
Biotec) were used to positively select plasma cells and enrich
malignant cell populations. Genomic DNA (gDNA) was
extracted from enriched plasma cells using AllPrep DNA
extraction kit (Qiagen) following manufacturer’s instructions.
Normal gDNA for three of these patients was collected and
extracted from buccal cells with Gentra Puregene Buccal Cell
Kit (Qiagen) following manufacturer’s instructions. Eight
additional normal DNA were also extracted using the same
methodology and separately sequenced to constitute a pool of
normal DNA.
2.3 aCGH and CNV analysis
Plasma cells of the whole MM cohort were analyzed with the
SurePrint G3 Human CGH Microarray Kit 8 × 60K (Agi-
lent Technologies) according to manufacturer’s instructions,
and results were interpreted using the Cytogenomics soft-
ware (Agilent Technologies). The arrays were scanned with
a G2565CA microarray scanner (Agilent Technologies) and
the images were extracted and analyzed with CytoGenomics
software v2.0 (Agilent Technologies). An ADM-2 algorithm
(cut-oﬀ 6.0), followed by a ﬁlter to select regions with three
or more adjacent probes and a minimum average log2 ratio
of ±0.25, was used to detect copy number changes. The qual-
ity of each experiment was assessed by the measurement of
the derivative log ratio spread with CytoGenomics software
v2.0. Genomic positions were based on the UCSC human ref-
erence sequence (hg19) (NCBI build 37 reference sequence
assembly).
2.4 Whole exome sequencing and CNV call
Fifty nanograms of double-stranded gDNA were used to pre-
pare libraries with a Nextera Rapid Capture Expanded Exome
Kit (Illumina) according to the manufacturer’s instructions.
Libraries were checked for integrity using Agilent High Sen-
sitivity DNA Kit (Agilent Technologies) after tagmentation
and after the last step of library preparation. Sequencing reac-
tions were performed on a HiSeq2000 sequencer (Illumina).
3 METHODS AND RESULTS
3.1 Whole exome sequencing and CNV call
The raw sequencing data were aligned on the Human refer-
ence genome (NCBI build 137 hg19) with the BWA software
(Li & Durbin, 2009). The resulting alignment BAM ﬁles went
through several ﬁltering and correcting steps (local realign-
ment, base quality score recalibration, low quality reads ﬁl-
tering, and PCR duplicate reads removal) performed using
the Genome Analysis Toolkit (McKenna et al., 2010) and the
Picard software package (http://picard.sourceforge.net/).
A slightly modiﬁed version of the coverage ﬁles gener-
ated by the CalculateHsMetrics tool of the Picard software
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package (using the PER_TARGET_COVERAGE software
option) was used as input of the ExomeCNV software (ver-
sion 1.4).
For three tumor samples for which matched normal tissue
was available, two CNV proﬁles were called using the rec-
ommended parameters of ExomeCNV: one with the matched
normal sample as control and the other one with a pool of
unrelated healthy samples as control.
The ExomeCNV input ﬁle representing the pool of eight
unrelated healthy samples is generated thanks to a Perl script
that averages the coverage and average_coverage columns
of the Exome CNV input ﬁle among all unrelated healthy
samples.
The Perl scripts used to convert the output ﬁles of the Cal-
culateHsMetrics tool to input ﬁles suitable for ExomeCNV
and to generate the ExomeCNV input ﬁle for the pool are
available as supplementary data.
3.2 CNV profiles comparison
Several analyses were performed to compare the CNV pro-
ﬁles obtained through aCGH, Exome CNV with the matched
normal sample as control and Exome CNV with the pool of
eight unrelated healthy samples as control. Only autosomes
were considered in this study.
For the sake of brevity, for each sample𝑆𝑘, let us note𝑆𝑘𝐶 ,
𝑆𝑘𝑀 , 𝑆𝑘𝑃 , respectively, the CNV proﬁle obtained through
arrayCGH, the CNV proﬁle obtained through the Exome
CNV software with the matched normal sample as control and
the CNV proﬁle obtained through the Exome CNV software
with the pool of eight unrelated healthy samples as control.
3.3 Deletion/Amplification ratio
The deletion/ampliﬁcation ratio has been determined for each
CNV proﬁle, as to detect possible method-speciﬁc biases.
Ampliﬁcations and deletions with a |LRR| (|Log-R-Ratio|)
smaller than 0.29 (corresponding to alterations whose copy
number is approximately between 1.6 and 2.4) were consid-
ered to be inconsistent and were ﬁltered out for all CNV pro-
ﬁles. The ratio is based on the total number of deleted and
ampliﬁed bases, as this gives a more reliable information than
a ratio based on the count of ampliﬁcations and deletions. As
shown on Figure 1, both Samples 1 and 3 show close dele-
tion/ampliﬁcation ratios and absolute values for each of the
three proﬁles. No speciﬁc bias in favor of ampliﬁcation or
deletion is found in the CNV proﬁles obtained through Exome
CNV software with the pool of eight unrelated healthy sam-
ples as control. Interestingly, for Sample 2, the absolute val-
ues for the number of deleted bases are very similar, but the
number of ampliﬁed bases varies. 𝑆2𝑃 thus shows a dele-
tion/ampliﬁcation ratio much more similar to 𝑆2𝐶 than 𝑆2𝑀 .
This is explained by the fact that most of the missing ampli-
ﬁcations in 𝑆2𝑀 are present but have in fact a low LRR and
are ﬁltered out. Due to their low LRR, these ampliﬁcations
are undistinguishable from false positives.
3.4 CNV size distribution
To know if the use of a pool as reference had an impact on the
size of detected CNV, we determined the CNV size distribu-
tion for each proﬁle (see Fig. 2). Ampliﬁcations and deletions
with a |LRR| smaller than 0.29 were ﬁltered out. Although the
absolute count of very small CNVs (< 1 kb) is higher in pro-
ﬁles obtained through the use of a pool as reference, their rel-
ative contribution remains unchanged and insigniﬁcant (see
Additional File 1).
3.5 Confusion matrix
For both exome-based CNV proﬁles of each sample (𝑆𝑘𝑀
and 𝑆𝑘𝑃 ), TPR (true-positive rate), FPR (false-positive rate),
TNR (true-negative rate), and FNR (false-negative rate) were
determined separately for ampliﬁcations and deletions, as
shown in Table 1. Ampliﬁcations and deletions with a |LRR|
smaller than 0.29 were ﬁltered out. Interestingly, CNV pro-
ﬁles obtained through the use of a pool of eight unrelated
healthy individuals yield overall slightly better results. The
low TPR value for the ampliﬁcations of 𝑆2𝑀 can again be
explained by LRR values not passing the aforementioned
threshold.
3.6 CNV profile distance metric
Each of the previous analyses highlights potential biases, sim-
ilarities, and/or discrepancies between CNV proﬁles but, due
to methodological speciﬁcities, none gives a global picture
of the real distance between proﬁles, as even the outcomes
of the confusion matrix do not take into accounts the varia-
tion of copy number in ampliﬁcations and deletions (e.g., if
the reference contains a segment of copy-number 3 and the
tested proﬁle contains a segment of copy-number 4 at the
same locus, both proﬁles are considered to contain an ampli-
ﬁcation, no diﬀerence penalty is taken into account and the
confusion matrix values are the same as they would be if both
segments shared the exact same copy-number).
We propose a new distance metric, designed to compare
CNV proﬁles, which takes into account the exact LRR val-
ues, thus giving a more precise insight, independently of the
technique used to obtain the proﬁles.
Each CNV proﬁle is represented as a combination of
sequences of LRR segments of ﬁxed size, one sequence for
each chromosome.
Let 𝑗, 𝑘 be the indexes of two CNV proﬁles.
At each segment 𝑠, the diﬀerence in terms or LRR between
the two proﬁles is noted as
|||𝐿𝑅𝑅𝑠𝑗 − 𝐿𝑅𝑅𝑠𝑘
||| .
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F IGURE 1 Ampliﬁcation and deletion ratios for each sample. Bar heights represent the percentage of ampliﬁed or deleted bases. The total number of
ampliﬁed or deleted megabases is written inside each bar
F IGURE 2 CNV size distribution. Bar heights represent the relative contribution of each group
From each LRR value, the corresponding copy-number for
autosomes can be derived by
𝐶𝑁 = 2 × 2𝐿𝑅𝑅.
The diﬀerence in terms of copy number at each segment 𝑠







We deﬁned the distance metric between two CNV proﬁles
as the sum of distances between all segments divided by the
total number of segments.









where 𝑆 is the total number of segments.
The relation between the genome size, segment size, and
total number of segments is noted:
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TABLE 1 Confusion Matrix
S1_M S1_P S2_M S2_P S3_M S3_P
AMP TPR 97.29 96.58 12.31 99.24 99.96 97.01
FPR 2.71 3.42 87.69 0.76 0.04 2.99
TNR 63.83 82.14 99.98 97.79 89.23 92.63
FNR 36.17 17.86 0.02 2.21 10.77 7.37
DEL TPR 94.83 96.43 98.01 98.01 96.82 95.88
FPR 5.17 3.57 1.99 1.99 3.18 4.12
TNR 97.5 97.59 99.63 97.4 68.06 89.29
FNR 2.5 2.41 0.37 0.6 31.94 10.71
TABLE 2 Distance Between Each CNV Proﬁle
Sheet 1
S1_M S1_P S1_C S2_M S2_P S2_C S3_M S3_P S3_C
S1_M 0 1.4 1.9 3.5 3.5 3.5 4.8 4.7 4.1
S1_P 1.4 0 1.3 3.5 3.1 3.3 4.5 4.5 4.2
S1_C 1.9 1.3 0 2.6 2.5 2.3 4.6 4.4 4.2
S2_M 3.5 3.5 2.6 0 0.7 0.4 4 3.7 3.6
S2_P 3.5 3.1 2.5 0.7 0 0.5 3.8 3.6 3.7
S2_C 3.5 3.3 2.3 0.4 0.5 0 4 3.6 3.5
S3_M 4.8 4.5 4.6 4 3.8 4 0 1 2
S3_P 4.7 4.5 4.4 3.7 3.6 3.6 1 0 2
S3_C 4.1 4.2 4.2 3.6 3.7 3.5 2 2 0
𝐺 = 𝑆 × 𝐿, where 𝐺 is the genome size and 𝐿 is the seg-
ment size
A Perl script implementing this distance metric is available
as supplementary data. For clarity, all distance values have
been multiplied by 10.
Table 2 shows distance values computed for all possi-
ble combinations of the nine CNV proﬁles generated based
on our cohort. Several observations can be made based on
these results. For each sample, the smallest distance is always
found between the two proﬁles obtained through the use of
ExomeCNV. For each sample, the distance between the aCGH
proﬁle and the ExomeCNV proﬁle using a pool of eight unre-
lated healthy individual as control is similar to the distance
between the aCGH proﬁle and the ExomeCNV proﬁle using
the matched paired healthy tissue as control. The intersample
distance, whatever the technique, is always greater than the
intrasample distance.
3.7 Additional validation
The same analyses were performed on 7 MM samples for
which no matched normal tissue was available. Here, only
𝑆𝑘𝑃 and 𝑆𝑘𝐶 (respectively the proﬁle obtained through
ExomeCNV with a pool, and the proﬁle obtained through
aCGH) were compared.
The proportion of deletion to ampliﬁcation does not show
any speciﬁc bias and the ampliﬁed and deleted bases counts
are highly correlated between 𝑆𝑘𝑃 and 𝑆𝑘𝐶 (Pearson corre-
lation coeﬃcient of 0.975, see Additional ﬁle 2 for the count
of deleted and ampliﬁed bases).
The confusion matrix values obtained when comparing
𝑆𝑘𝑃 to 𝑆𝑘𝐶are relatively similar to the previous values
obtained. The average values for the true-positive rate and
the true negative rate for the ampliﬁcations are respectively
89.85% and 92.41%. The corresponding values for the dele-
tions are respectively 97.04% and 74.97% (see Additional ﬁle
3 for the complete data).
The distance metric was computed for each pair of the 14
proﬁles. As previously, for each sample the intrasample dis-
tance is always smaller than all intersamples distances involv-
ing this sample. The average value for intrasample distance
was 1.8 ± 0.2, while the average value for intersample dis-
tance was 3.25 ± 0.16. All distance values are shown in addi-
tional ﬁle 4.
4 DISCUSSION
To date, several CNV detection tools catered to WES data
exist, some of these tools make use of paired healthy DNA
as references, while others use diﬀerent methodologies and
do not need such references. Paired methods that use the
read depth or read count ratio are often more eﬀective but
inadequate for the analysis of a sample without corresponding
healthy DNA.
Although ExomeCNV is a method based on read depth
using paired healthy DNA as control, its authors suggested
that a pool of unrelated healthy individuals could also be used
as reference. Based on preliminary results, the authors also
emit the hypothesis that the use of such a pool could lead
to more reliable results thanks to a reduction in variance of
depth-of-coverage (Sathirapongsasuti et al., 2011). No thor-
ough analysis had previously been performed to assess the
validity of these claims. Furthermore, we propose a new, bet-
ter suited, way to compare CNV proﬁles, independently of the
technique used to obtain said proﬁle and tested this method on
a small number of multiple myeloma samples.
Research and clinical application of WES for CNV detec-
tion are most useful in the cancer ﬁeld. Indeed, many clini-
cally actionable genetic changes have been described. These
changes include CNV (deletions, ampliﬁcations) as well as
punctual mutations. Their identiﬁcation has an increasing
clinical impact as they deﬁne the prognosis and can also pre-
dict treatment response or resistance, paving the way toward
personalized medicine and the use of speciﬁc targeted treat-
ments. The molecular diagnosis remains, however, diﬃcult
as it is presently based on limited amounts of DNA (from
biopsies) and has to deal with the tumor heterogeneity. More-
over, large retrospective studies based on samples stored in
biobanks are needed to validate genetic biomarkers in vari-
ous cancers.
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In our study we explored MM which is characterized by
a high genomic instability. Indeed, alterations with clinical
impact like monosomy 13 and trisomy of odd chromosomes
are easily detected with this method while partial alterations
of chromosome 1 and 17 sometimes show some approxima-
tion concerning the exact breakpoints. Even if the impact of
punctual mutations in this type of cancer is still unclear, a
few studies performed by NGS show a high level of muta-
tions implicating genes frequently involved in cancers and
coding for therapeutic targets (Chapman et al., 2011; Lohr
et al., 2014). However, as it has been demonstrated that MM is
characterized by a high level of clonal heterogeneity accord-
ing to the stage of the disease, WES allows an evaluation of
each clonal population proportion at the diﬀerent stages of
the disease (Walker et al., 2014). It could therefore be help-
ful for the follow-up of patients to evaluate clonal evolution
in response to treatment at relapse. A simple method identify-
ing point mutations and CNVs is certainly required for such
a clinical application.
In conclusion, our data indicate that a reliable picture of
CNV alterations inMM samples could be obtained fromWES
in the absence of a matched healthy sample. As our data were
obtained on a very low number ofMMsamples, theywill need
to be conﬁrmed on larger cohorts of other cancer types. If this
can be done, it would considerably facilitate genomic studies
on biobank material as well as in the clinical setting as the
collection, study and data storage for matched normal DNA is
expensive and generates cancer-unrelated incidental ﬁndings.
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